An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Pomalidomide; Prednisone; Prednisone; Thalidomide
Indications Multiple myeloma
Focus Adverse reactions; Registrational
Acronyms EQUULEUS
Sponsors Janssen Research & Development

11 Mar 2024 Status changed from active, no longer recruiting to completed.
10 Oct 2023 Planned End Date changed from 31 Oct 2023 to 29 Dec 2023.
01 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com